Urologix Inc. (ULGX, Financial) filed Annual Report for the period ended 2010-06-30.
Urologix Inc. has a market cap of $13.6 million; its shares were traded at around $0.94 with and P/S ratio of 0.9. ULGX is in the portfolios of Chuck Royce of Royce& Associates.
During the fiscal years ended June 30, 2010, 2009, and 2008, we spent $1.8 million, $2.4 million, and $2.8 million, respectively, on our research and development efforts. As of June 30, 2010, we employed 12 individuals in our research and development department.
The national average reimbursement rate in the physician office setting which is a global fee paid entirely to the urologist - is currently $2,430 for our Cooled ThermoTherapy treatment. The CMS published the Physician Fee Schedule (PFS) final rule for calendar 2010 on October 30, 2009. Since publication, Congress has acted four times to temporarily adjust the 2010 Medicare reimbursement for all physician payments. These adjustments are to offset broader prescribed reimbursement cuts to Medicare driven by the Sustainable Growth Rate (SGR) formula. The current temporary adjustment expires November 30, 2010. If Congress fails to act to extend the temporary adjustment to the Medicare Physician Fee Schedule, the level of Medicare reimbursement in the physician office setting for Cooled ThermoTherapy will decline to $1,869. While Congress has acted four times since the publication of the 2010 final rule to delay the impacts from the SGR, we do not know when nor if these adjustments will be extended for the final month of calendar year 2010 and calendar year 2011. We are monitoring these developments closely and will continue to execute on our active reimbursement strategy.
Urologists who perform Cooled ThermoTherapy procedures in an ASC are reimbursed under the two-part system in which the ASC receives a fixed fee of $1,868 in the 2010 PFS as compared to $1,849 in 2009, while the urologist performing the treatment is reimbursed $601 currently. In the hospital outpatient setting, which is not affected by changes in the SGR, the national average total reimbursement is $3,147 for calendar year 2010 compared to $3,026 in calendar year 2009. In the hospital outpatient setting, the urologist performing the treatment is reimbursed $601.
Read the The complete Report
Urologix Inc. has a market cap of $13.6 million; its shares were traded at around $0.94 with and P/S ratio of 0.9. ULGX is in the portfolios of Chuck Royce of Royce& Associates.
Highlight of Business Operations:
The aggregate value of the Companys Common Stock held by non-affiliates of the Company was approximately $25,234,677 as of the last day of the Companys most recently completed second fiscal quarter, December 31, 2009, when the last reported sales price was $1.85.During the fiscal years ended June 30, 2010, 2009, and 2008, we spent $1.8 million, $2.4 million, and $2.8 million, respectively, on our research and development efforts. As of June 30, 2010, we employed 12 individuals in our research and development department.
The national average reimbursement rate in the physician office setting which is a global fee paid entirely to the urologist - is currently $2,430 for our Cooled ThermoTherapy treatment. The CMS published the Physician Fee Schedule (PFS) final rule for calendar 2010 on October 30, 2009. Since publication, Congress has acted four times to temporarily adjust the 2010 Medicare reimbursement for all physician payments. These adjustments are to offset broader prescribed reimbursement cuts to Medicare driven by the Sustainable Growth Rate (SGR) formula. The current temporary adjustment expires November 30, 2010. If Congress fails to act to extend the temporary adjustment to the Medicare Physician Fee Schedule, the level of Medicare reimbursement in the physician office setting for Cooled ThermoTherapy will decline to $1,869. While Congress has acted four times since the publication of the 2010 final rule to delay the impacts from the SGR, we do not know when nor if these adjustments will be extended for the final month of calendar year 2010 and calendar year 2011. We are monitoring these developments closely and will continue to execute on our active reimbursement strategy.
Urologists who perform Cooled ThermoTherapy procedures in an ASC are reimbursed under the two-part system in which the ASC receives a fixed fee of $1,868 in the 2010 PFS as compared to $1,849 in 2009, while the urologist performing the treatment is reimbursed $601 currently. In the hospital outpatient setting, which is not affected by changes in the SGR, the national average total reimbursement is $3,147 for calendar year 2010 compared to $3,026 in calendar year 2009. In the hospital outpatient setting, the urologist performing the treatment is reimbursed $601.
Read the The complete Report
